1-(6-氯-1,3-苯并噻唑-2-基)肼 | 51011-54-2

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 1-(6-氯-1,3-苯并噻唑-2-基)肼
• 中文别名: (6-氯-1,3-苯并噻唑-2-基)肼；6-氯-2-肼基苯并噻唑
• 英文名称: 6-chloro-2-hydrazinobenzothiazole
• 英文别名: (6-chlorobenzothiazol-2-yl)-hydrazine；6-Chloro-2-hydrazinylbenzo[d]thiazole；(6-chloro-1,3-benzothiazol-2-yl)hydrazine
• CAS: 51011-54-2
• 化学式: C₇H₆ClN₃S
• mdl: MFCD00832729
• 分子量: 199.664
• InChiKey: JBAIRAQEQLLZMN-UHFFFAOYSA-N

物化性质

• 熔点：
  263 °C
• 沸点：
  387.1±44.0 °C(Predicted)
• 密度：
  1.68±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2934200090
• 安全说明：
  S26,S36/37/39

SDS

Name:	1-(6-Chloro-1,3-benzothiazol-2-yl)hydrazine, 97% Material Safety Data Sheet
Synonym:
CAS:	51011-54-2

Section 1 - Chemical Product MSDS Name: 1-(6-Chloro-1,3-benzothiazol-2-yl)hydrazine, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51011-54-2	1-(6-Chloro-1,3-benzothiazol-2-yl)hydr	97%	unlisted

+++++
Hazard Symbols: XN

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Harmful by inhalation, in contact with skin and if swallowed. Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 51011-54-2: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 212 - 215 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H6ClN3S
Molecular Weight: 199.66

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 51011-54-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(6-Chloro-1,3-benzothiazol-2-yl)hydrazine - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with skin and if swallowed. R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 36/37/39 Wear suitable protective clothing, gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 51011-54-2: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 51011-54-2 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 51011-54-2 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 6/10/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(6-氯-1,3-苯并噻唑-2-基)肼 在 吡啶 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 5.0h， 生成 8-chloro-2-hydroxymethyl[1,2,4]triazino[3,4-b][1,3]benzothiazole-3,4-dione
  参考文献：
  名称：

  Kuberkar, Sharad V.; Bhosale, Vijay N.; Vartale, Sambhaji P., Journal of Chemical Research, 2005, # 10, p. 632 - 635

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯苯基硫脲 在 盐酸 、 溴 、 一水合肼 作用下， 以 乙二醇 为溶剂， 生成 1-(6-氯-1,3-苯并噻唑-2-基)肼
  参考文献：
  名称：

  具有抗糖尿病作用的新型胡椒碱衍生物作为PPAR-γ激动剂

  摘要：

  胡椒碱是负责黑胡椒辛辣的生物碱。在这项研究中，从分离胡椒碱胡椒L.碱性条件下进行水解，得到胡椒酸和用作前体进行含有苯并噻唑部分20个胡椒碱衍生物的合成。通过OGT试验评估所有苯并噻唑衍生物的抗糖尿病潜力，然后在STZ诱导的糖尿病模型中评估活性衍生物。观察到二十种新型胡椒碱类似物中有九种（5b，6a-h）与罗格列酮（标准品）相比，具有明显更高的抗糖尿病活性。此外，评估了这些活性衍生物作为PPAR-γ激动剂的作用，证明了其作用机理。还研究了服用活性衍生物后对体重，脂质过氧化和肝毒性的影响，以进一步确立这些衍生物作为治疗糖尿病副作用较小的先导分子。

  DOI：

  10.1111/cbdd.12760

文献信息

• Ferulic acid and benzothiazole dimer derivatives with high binding affinity to β-amyloid fibrils
  作者：Seong Rim Byeon、Yun Jung Jin、Soo Jeong Lim、Ji Hoon Lee、Kyung Ho Yoo、Kye Jung Shin、Seung Jun Oh、Dong Jin Kim

  DOI：10.1016/j.bmcl.2007.04.079

  日期：2007.7

  New ferulic acid and benzothiazole dimer derivatives were synthesized and evaluated by in vitro competition assay using [(125)I]TZDM for their specific binding affinities to Abeta fibrils. In particular, 4a showed the most excellent binding affinity (K(i)=0.53 nM), compared to PIB (K(i)=0.77 nM), for benzothiazole binding sites of Abeta(1-42) fibrils. This result suggests a possibility of a potential

  合成了新的阿魏酸和苯并噻唑二聚体衍生物，并通过体外竞争试验使用[（125）I] TZDM评估了它们与Abeta原纤维的特异性结合亲和力。特别地，与PIB（K（i）= 0.77 nM）相比，4a对Abeta（1-42）原纤维的苯并噻唑结合位点显示出最优异的结合亲和力（K（i）= 0.53 nM）。该结果表明潜在的AD诊断探针用于检测Abeta原纤维的可能性。
• Antimycobacterial and antimicrobial study of new 1,2,4-triazoles with benzothiazoles
  作者：Navin B. Patel、Imran H. Khan、Smita D. Rajani

  DOI：10.1002/ardp.201000061

  日期：2010.11

  In this study, we report the antimycobacterial and antimicrobial evaluation of newly synthesized 3‐(3‐pyridyl)‐5‐(4‐methoxyphenyl)‐4‐(N‐substituted‐1,3‐benzothiazol‐2‐amino)‐4H‐1,2,4‐triazole 6a–j in good yields. All the synthesized compounds have been established by elemental analysis, IR, 1H NMR, 13C‐NMR and Mass spectral data. In‐vitro antimycobacterial activity was carried out against (Mycobacterium

  在这项研究中，我们报告了新合成的 3-(3-吡啶基)-5-(4-甲氧基苯基)-4-(N-取代的-1,3-苯并噻唑-2-氨基)-4H-的抗分枝杆菌和抗菌评价1,2,4-三唑 6a – j 收率良好。所有合成的化合物均已通过元素分析、IR、1H NMR、13C-NMR和质谱数据确定。使用Lowenstein-Jensen培养基对（结核分枝杆菌）H37Rv菌株进行体外抗分枝杆菌活性，对两种革兰氏阳性菌（金黄色葡萄球菌、化脓性链球菌）、两种革兰氏阴性菌（大肠杆菌、假单胞菌）物种（白色念珠菌、黑曲霉、棒状曲霉）使用肉汤微量稀释法。化合物 2e、6a、6g、6h、
• DESIGN, SYNTHESIS, DOCKING STUDIES AND BIOLOGICAL EVALUATION OF 2-PHENYL-3-(SUBSTITUTED BENZO[d] THIAZOL-2-YLAMINO)-QUINAZOLINE-4(3H)-ONE DERIVATIVES AS ANTIMICROBIAL AGENTS
  作者：Pooja Pisal、Meenakshi Deodhar、Amol Kale、Ganesh Nigade、Smita Pawar

  DOI：10.22159/ijpps.2018v10i10.28480

  日期：——

  Objective: A new series 2-phenyl-3-(substituted benzo[d] thiazol-2-ylamino)-quinazoline-4(3H)-one was prepared by the fusion method by reacting 2-phenyl benzoxazine with 2-hydrazino benzothiazole and it was evaluated for their antimicrobial activity against gram positive, gram negative bacteria and fungi.Methods: Titled compounds were synthesized by fusion reactions. These compounds were evaluated by in vitro antibacterial and antifungal activity using the minimum inhibitory concentration and zone of inhibition methods. The synthesized compounds were characterized with the help of infrared, NMR and mass spectral studies. The benzothiazole moiety and the quinazoline ring have previously shown DNA gyrase inhibition and target related antibacterial activity. Thus, molecular docking studies of synthesized compounds were carried out (PDB: 3G75) to study the possible interaction of compounds with the target. The batch grid docking was performed to determine the probable.Results: These compounds showed significant activity against gram positive and gram negative bacteria as well against the fungi. The compound A5 was found to be active against B. subtilis, P aeruginosa and C. albican at 12.5 µg/ml MIC. The compound A3 was found to be active against all microbial strains selected at 25 and 12.5 µg/ml MIC.Conclusion: Though the relationship between the activities shown by these compounds in, the antimicrobial study is still to be established, the docking studies conducted found to be consistent with antimicrobial results. Thus the results indicate that the designed structure can be a potential lead as an antimicrobial agent.

  目标：通过融合方法，将2-苯基苯并噁嗪与2-叠氮基苯并噻唑反应制备了一系列新的2-苯基-3-(取代苯并[d]噻唑-2-基氨基)-喹唑啉-4(3H)-酮，并对其针对革兰氏阳性菌、革兰氏阴性菌和真菌的抗菌活性进行了评估。方法：通过融合反应合成了所述化合物。利用最小抑制浓度和抑制区域方法评估了这些化合物的体外抗菌和抗真菌活性。通过红外、核磁共振和质谱研究对合成的化合物进行了表征。苯并噻唑基团和喹唑啉环先前已显示出DNA酶抑制和靶相关抗菌活性。因此，对合成化合物进行了分子对接研究（PDB：3G75），以研究化合物与靶的可能相互作用。进行了批量网格对接以确定可能的结果。结果：这些化合物对革兰氏阳性和革兰氏阴性细菌以及真菌表现出显著活性。化合物A5对枯草杆菌、铜绿假单胞菌和白念珠菌表现出12.5 µg/ml的MIC活性。化合物A3对所有选择的微生物菌株在25和12.5 µg/ml的MIC下表现出活性。结论：尽管这些化合物在抗菌研究中表现出的活性之间的关系尚待建立，但进行的对接研究与抗菌结果一致。因此，结果表明设计的结构可能是一种潜在的抗菌剂。
• Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles
  作者：Navin B. Patel、Imran H. Khan、Smita D. Rajani

  DOI：10.1016/j.ejmech.2010.06.031

  日期：2010.9

  multistep synthesis sequence beginning with ethyl nicotinoate 3 which on treatment with hydrazine hydrate yields nicotinoyl hydrazide 4. Intermolecular cyclisation of 4 with 4-methylbenzoic acid in presence of phosphorous oxy chloride affords 2-(3-pyridyl)-5-(4-methylphenyl)-1,3,4-oxadiazole 5. Condensation of 5 with various substituted 2-hydrazino benzothiazole 2a–j results in 3-(3-pyridyl)-5-(4-meth

  通过获得三唑类似物。从烟酸乙酯3开始的多步合成序列 ，在用水合肼处理时产生烟酰酰肼4。在氯氧化磷存在下，用4-甲基苯甲酸将4进行分子间环化，得到2-（3-吡啶基）-5-（4-甲基苯基）-1,3,4-恶二唑5。5与各种取代的2-肼基苯并噻唑2a – j缩合，生成3-（3-吡啶基）-5-（4-甲基苯基）-4-（N-取代-1,3-苯并噻唑-2-氨基）-4 H -1,2,4-三唑6a – j类似物。所有化合物均已通过元素分析，IR，1 H NMR，13 C NMR和质谱数据进行了表征。使用Lowenstein-Jensen培养基对结核分枝杆菌H 37 Rv菌株进行了体外抗结核活性，并采用肉汤微量稀释法对各种细菌和真菌进行了抗菌活性。化合物2e，6a，6b，6c，6d，6g，6h和6i作为有希望的抗菌药物出现。还观察到有希望的抗微生物剂已被证明是更好的抗结核药。与利福平相比，化合物6j显示出更好的抗结核活性。
• Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles
  作者：Navin B. Patel、Imran H. Khan、Christophe Pannecouque、Erik De Clercq

  DOI：10.1007/s00044-012-0129-4

  日期：2013.3

  In an attempt to synthesize pharmacologically active molecules, we report here the synthesis and in vitro anti-HIV, antimycobacterial and antimicrobial activity of various series of 3-(3-pyridyl)-5-(4-substitutedphenyl)-4-(N-substituted-1,3-benzothiazol-2-amino)-4H-1,2,4-triazole. The anti-HIV activity of the title compounds was evaluated as selective human immunodeficiency virus type-1 and -2 (HIV-1

  在试图合成药理学活性分子，我们在这里报告的合成和体外抗HIV，各种系列3-（3-吡啶基）的抗分支杆菌的和抗微生物活性-5-（4-取代苯基）-4-（ñ -取代的-1,3-苯并噻唑-2-氨基）-4 H -1,2,4-三唑。评价了标题化合物的抗HIV活性，包括选择性的1型和2型人类免疫缺陷病毒（HIV-1，HIV-2 RT）抑制剂，使用Lowenstein-Jensen琼脂法的针对H 37 Rv的抗结核活性以及针对H 37 Rv的抗菌活性。某些细菌和真菌菌株采用肉汤微稀释法。FTIR，1 H-NMR，13C-NMR和质谱数据以及元素分析。